BiotechTube
UNION therapeutics

UNION therapeutics

Copenhagen, Denmark· Est.
uniontherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $155M

Overview

UNION therapeutics is a Danish clinical-stage biotech founded in 2017, targeting high-need immunological conditions such as atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. Its lead asset, orismilast, is a PDE4 inhibitor in Phase 2 development, with recent data presented in ulcerative colitis and a novel biomarker profiling approach published. The company is privately funded, pre-revenue, and leverages a seasoned leadership team with deep drug development and commercialization experience to advance its pipeline.

ImmunologyDermatologyGastroenterology

Technology Platform

Clinical development focused on novel biomarker strategies (e.g., tape-stripping with Olink proteomics) to demonstrate mechanism of action and guide development of small molecule PDE4 inhibitors.

Funding History

2
Total raised:$155M
Series C$100M
Series B$55M

Opportunities

The large and growing immunology market, particularly for oral therapies in dermatology and gastroenterology, presents a significant commercial opportunity.
Success in one indication with orismilast could rapidly enable expansion into other inflammatory diseases, leveraging the same core asset.
Advanced biomarker strategies may enable more efficient clinical development and stronger differentiation.

Risk Factors

Clinical failure of the lead asset, orismilast, would jeopardize the entire company.
Dependence on private funding creates financial vulnerability in a volatile capital market.
The intense competition from both large pharma and other biotechs in immunology requires a highly differentiated product profile.

Competitive Landscape

UNION competes in the crowded PDE4 inhibitor space (e.g., crisaborole, apremilast) and the broader immunology market dominated by biologic therapies. Key competitors include large pharmaceutical companies with extensive dermatology portfolios (e.g., AbbVie, Eli Lilly, Pfizer) and other biotechs developing oral agents. Differentiation will rely on orismilast's improved efficacy/tolerability profile and its application in high-need areas like hidradenitis suppurativa.

More companies in Small Molecule Drugs →More companies in Denmark →